Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: February 19, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for PF-06650833

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the drug development status for PF-06650833?

PF-06650833 is an investigational drug.

There have been 8 clinical trials for PF-06650833. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2016.

The most common disease conditions in clinical trials are Hidradenitis Suppurativa, Hidradenitis, and Arthritis, Rheumatoid. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There are three US patents protecting this investigational drug and fifty international patents.

Recent Clinical Trials for PF-06650833
A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis SuppurativaPfizerPhase 2
Bioavailability and Food Effect Study of Two Formulations of PF-06650833PfizerPhase 1

See all PF-06650833 clinical trials

Clinical Trial Summary for PF-06650833

Top disease conditions for PF-06650833
Top clinical trial sponsors for PF-06650833

See all PF-06650833 clinical trials

US Patents for PF-06650833

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-06650833   Start Trial Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc. (New York, NY)   Start Trial
PF-06650833   Start Trial Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc. (New York, NY)   Start Trial
PF-06650833   Start Trial Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-06650833

Drugname Country Document Number Estimated Expiration Related US Patent
PF-06650833 Argentina 099955 2034-04-04   Start Trial
PF-06650833 Australia 2015242291 2034-04-04   Start Trial
PF-06650833 Canada 2944475 2034-04-04   Start Trial
PF-06650833 Chile 2016002524 2034-04-04   Start Trial
PF-06650833 China 106458912 2034-04-04   Start Trial
PF-06650833 Costa Rica 20160456 2034-04-04   Start Trial
PF-06650833 Cuba 20160149 2034-04-04   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.